Diabetes drugs linked to higher risk for rare but deadly complication 

Diabetes drugs linked to higher risk for rare but deadly complication – CBS News

 

 

A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of the disease called ketoacidosis, a new study warns.

SGLT2 inhibitors include prescription medications such as canagliflozin, dapagliflozin and empagliflozin. Brand names are Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance and Glyxambi.

These drugs first became available in 2013, but in 2015 the U.S. Food and Drug Administration issued a warning about an increased risk for diabetic ketoacidosis when SGLT2 inhibitors are used.

The condition typically occurs in people with type 1 diabetes. And while it is uncommon in people with type 2 diabetes, case reports have shown it can occur with type 2 disease, according to the study authors.

 

 

Read more: Diabetes drugs linked to higher risk for rare but deadly complication – CBS News

 

 

FAIR USE STATEMENT
This site may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. The Uncensored Report (“the site”) is making such material available in an effort to further understanding of political, social, economic, and scientific issues, etc. The site asserts this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law.

Please follow and like us:

Leave a Reply

Your email address will not be published. Required fields are marked *